JAK2 and myeloid neoplasm: Hence, we believe that this work uncovered a new signaling dynamic that enhances our understanding of compartmentalized RAS signaling, suggesting that targeting RAB27B may be therapeutically useful in oncogenic CBL/JAK2 and RAS driven myeloid malignancies.